The aim of this study was to explore the effects of Dll4 antibody therapy alone and in combination with approved VEGF inhibitors on tumor growth and perfusion in patient-derived xenograft (PDX) ccRCC models. Here, DLL4 is linked to nonpapillary renal cell carcinoma.